Bank of New York Mellon’s XBiotech XBIT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $90.5K | Hold |
39,355
| – | – | ﹤0.01% | 4205 |
|
|
2026
Q1 | $92.5K | Sell |
39,355
-9,096
| -19% | -$22K | ﹤0.01% | 4111 |
|
|
2025
Q4 | $116K | Hold |
48,451
| – | – | ﹤0.01% | 4095 |
|
|
2025
Q3 | $129K | Hold |
48,451
| – | – | ﹤0.01% | 4081 |
|
|
2025
Q2 | $144K | Sell |
48,451
-42,609
| -47% | -$124K | ﹤0.01% | 4035 |
|
|
2025
Q1 | $295K | Hold |
91,060
| – | – | ﹤0.01% | 3710 |
|
|
2024
Q4 | $360K | Buy |
91,060
+6,328
| +7% | +$43.1K | ﹤0.01% | 3688 |
|
|
2024
Q3 | $655K | Sell |
84,732
-13,582
| -14% | -$89.2K | ﹤0.01% | 3364 |
|
|
2024
Q2 | $505K | Buy |
98,314
+49,863
| +103% | +$385K | ﹤0.01% | 3585 |
|
|
2024
Q1 | $394K | Sell |
48,451
-7,242
| -13% | -$41.5K | ﹤0.01% | 3660 |
|
|
2023
Q4 | $223K | Hold |
55,693
| – | – | ﹤0.01% | 3919 |
|
|
2023
Q3 | $229K | Hold |
55,693
| – | – | ﹤0.01% | 3911 |
|
|
2023
Q2 | $331K | Hold |
55,693
| – | – | ﹤0.01% | 3787 |
|
|
2023
Q1 | $192K | Hold |
55,693
| – | – | ﹤0.01% | 3937 |
|
|
2022
Q4 | $195K | Hold |
55,693
| – | – | ﹤0.01% | 3979 |
|
|
2022
Q3 | $201K | Hold |
55,693
| – | – | ﹤0.01% | 4014 |
|
|
2022
Q2 | $314K | Sell |
55,693
-23,181
| -29% | -$156K | ﹤0.01% | 3853 |
|
|
2022
Q1 | $681K | Buy |
78,874
+19,140
| +32% | +$192K | ﹤0.01% | 3526 |
|
|
2021
Q4 | $665K | Buy |
59,734
+828
| +1% | +$10.8K | ﹤0.01% | 3620 |
|
|
2021
Q3 | $763K | Buy |
58,906
+4,787
| +9% | +$76.3K | ﹤0.01% | 3559 |
|
|
2021
Q2 | $896K | Sell |
54,119
-7,286
| -12% | -$124K | ﹤0.01% | 3488 |
|
|
2021
Q1 | $1.05M | Buy |
61,405
+1,293
| +2% | +$24.1K | ﹤0.01% | 3302 |
|
|
2020
Q4 | $941K | Sell |
60,112
-2,889
| -5% | -$53.2K | ﹤0.01% | 3277 |
|
|
2020
Q3 | $1.2M | Sell |
63,001
-461
| -0.7% | -$7.96K | ﹤0.01% | 3008 |
|
|
2020
Q2 | $870K | Buy |
63,462
+15,481
| +32% | +$218K | ﹤0.01% | 3188 |
|
|
2020
Q1 | $510K | Sell |
47,981
-17,826
| -27% | -$290K | ﹤0.01% | 3360 |
|
|
2019
Q4 | $1.23M | Buy |
65,807
+7,708
| +13% | +$99.2K | ﹤0.01% | 3134 |
|
|
2019
Q3 | $607K | Buy |
58,099
+4,963
| +9% | +$40.4K | ﹤0.01% | 3428 |
|
|
2019
Q2 | $403K | Buy |
53,136
+36,415
| +218% | +$317K | ﹤0.01% | 3703 |
|
|
2019
Q1 | $184K | Sell |
16,721
-507
| -3% | -$4.11K | ﹤0.01% | 3903 |
|
|
2018
Q4 | $88K | Hold |
17,228
| – | – | ﹤0.01% | 3982 |
|
|
2018
Q3 | $55K | Sell |
17,228
-5
| -0% | -$19 | ﹤0.01% | 4106 |
|
|
2018
Q2 | $77K | Sell |
17,233
-44,263
| -72% | -$200K | ﹤0.01% | 4035 |
|
|
2018
Q1 | $329K | Buy |
61,496
+3,933
| +7% | +$18.1K | ﹤0.01% | 3761 |
|
|
2017
Q4 | $227K | Sell |
57,563
-15,759
| -21% | -$66.3K | ﹤0.01% | 3900 |
|
|
2017
Q3 | $321K | Sell |
73,322
-129
| -0.2% | -$609 | ﹤0.01% | 3740 |
|
|
2017
Q2 | $345K | Buy |
73,451
+1,883
| +3% | +$18K | ﹤0.01% | 3763 |
|
|
2017
Q1 | $1.18M | Sell |
71,568
-937
| -1% | -$12.3K | ﹤0.01% | 3150 |
|
|
2016
Q4 | $734K | Buy |
72,505
+4,698
| +7% | +$62.5K | ﹤0.01% | 3426 |
|
|
2016
Q3 | $913K | Buy |
67,807
+9,758
| +17% | +$143K | ﹤0.01% | 3221 |
|
|
2016
Q2 | $1.21M | Buy |
58,049
+44,902
| +342% | +$648K | ﹤0.01% | 3021 |
|
|
2016
Q1 | $125K | Buy |
13,147
+580
| +5% | +$4.8K | ﹤0.01% | 3914 |
|
|
2015
Q4 | $136K | Buy |
12,567
+84
| +0.7% | +$1.07K | ﹤0.01% | 3984 |
|
|
2015
Q3 | $187K | Buy |
12,483
+2,282
| +22% | +$39.9K | ﹤0.01% | 3928 |
|
|
2015
Q2 | $185K | Buy |
+10,201
| New | +$212K | ﹤0.01% | 3904 |
|
Other funds holding XBIT
GCP
TNB
SS
CIAM
Bank of New York Mellon's XBIT Position: Q2 2026 in Review
Bank of New York Mellon held its XBiotech (XBIT) position steady in Q2 2026 at 39,355 shares worth $90.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4205.
Bank of New York Mellon first reported a position in XBIT in Q2 2015 and has held it in 45 quarters since. The position peaked at $1.23M in Q4 2019. 8 funds tracked by Wall St. Rank hold XBIT as of Q2 2026.
- Bank of New York Mellon held 39,355 shares of XBiotech worth $90.5K as of Q2 2026.
- Bank of New York Mellon left its XBiotech share count unchanged in Q2 2026.
- XBiotech made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #4205 holding.
- Bank of New York Mellon first reported a position in XBiotech in Q2 2015 and has held it in 45 quarters since.
- Bank of New York Mellon's XBiotech position peaked at $1.23M in Q4 2019.
- 8 funds tracked by Wall St. Rank held XBiotech as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.